88IV - Public company info - Simcere Pharmaceutical Group Limited

Input the stock code or the company name

Simcere Pharmaceutical Group Limited, 02096.HK - Cash Flow	2022-12	2021-12	2020-12	2019-12	2018-12	2017-12
Net Cash Flow from Operating Activities	1,347,616	-187,270	251,399	1,037,660	930,500	1,062,550
Net Cash Flow from Return on Investments & Servicing of Finance	-154,742	-146,263	-51,048	-949,037	-565,192	-40,700
Interest Received	70,609	26,449	26,118	109,929	22,984	10,839
Interest Paid	-29,983	-70,848	-141,178	-148,313	-39,120	-51,539
Dividend Received	195,928	289,432	64,012	1,401	0	0
Dividend Paid	-391,296	-391,296	0	-912,054	-549,056	0
Others	0	0	0	0	0	0
Taxes (Paid) / Refunded	7,096	-14,700	-154,668	-264,857	-154,683	-123,474
Net Cash Flow from Investing Activities	-198,231	-751,384	438,953	-704,258	-495,385	-519,229
Additions to Fixed Assets	-342,815	-209,488	-352,841	-507,658	-335,216	-292,200
Disposal of Fixed Assets	273	5,906	936	3,197	357	850
Increase in Investments	-301,106	-522,377	-102,013	-1,410,055	-896,712	-1,407,764
Decrease in Investments	124,287	548,823	882,934	974,706	1,154,026	804,613
Net Cash Flow with Related Parties	-16,027	0	0	-129,821	58,252	33,417
Others	337,157	-574,248	9,937	365,373	-476,092	341,855
Net Cash Flow before Financing Activities	1,001,739	-1,099,617	484,636	-880,492	-284,760	379,147
Net Cash Flow from Financing Activities	-332,402	-1,162,387	2,494,800	47,417	899,461	-295,778
New Loans	916,932	1,027,150	2,056,618	2,605,640	1,646,831	774,459
Loans Repayment	-1,233,307	-2,505,137	-1,826,850	-1,917,712	-771,468	-851,156
Fixed Income/Debt Instruments	0	0	0	0	0	0
Repayment of Fixed Income/Debt Instruments	0	0	0	0	0	0
Equity Financing	0	0	3,002,661	0	0	0
Net Cash Flow with Related Parties	-16,027	0	0	-129,821	58,252	33,417
Others	0	315,600	-737,629	-510,690	-34,154	-252,498
Increase(Decrease) in Cash & Cash Equivalents	669,337	-2,262,004	2,979,436	-833,075	614,701	83,369
Cash & Cash Equivalents at Beginning of Year	973,139	3,270,241	354,804	1,187,647	572,584	489,333
Net Cash Flow due to Change in Exchange Rate/Others	15,124	-35,098	-63,999	232	362	-118
Cash & Cash Equivalents at End of Year	1,657,600	973,139	3,270,241	354,804	1,187,647	572,584
Currency	Renminbi	Renminbi	Renminbi	Renminbi	Renminbi	Renminbi
Unit
Auditor's Opinion	1	1	1	0	0	0

Notes:1–Unqualified; 2–Unqualified ( not qualified in respect of fundamental uncertainly because of proper disclosure); 3–Qualified

88iv | Home | Login

Mobile | Full

Suntek Computer Systems Limited.

Public company info - Simcere Pharmaceutical Group Limited , 02096.HK